Last reviewed · How we verify
Arista
At a glance
| Generic name | Arista |
|---|---|
| Sponsor | Virtua Health, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Modifications to Radical Prostatectomy (PHASE3)
- EFFICACY of INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION on the POSTOPERATIVE BLOOD LOSS in PATIENTS UNDERGOING RARP for the TREATMENT of PROSTATE CANCER (NA)
- Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion. (NA)
- Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study (PHASE1)
- Arista for ALT Donor Sites to Reduce Drain Output (NA)
- Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System (NA)
- Trial Evaluating Use of Arista in Total Thyroidectomy (NA)
- Analysis of Hemostatic Agents Compared to Physiologic Hemostasis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arista CI brief — competitive landscape report
- Arista updates RSS · CI watch RSS
- Virtua Health, Inc. portfolio CI